|
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
|
17 October 2019 |
|
AstraZeneca divests rights for Losec to Cheplapharm
|
01 October 2019 |
|
Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial
|
27 September 2019 |
|
AstraZeneca amends collaboration with Ironwood for Linzess in China
|
19 September 2019 |
|
FDA grants Fast Track designation for Farxiga in heart failure
|
17 September 2019 |
|
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
|
04 September 2019 |
|
FDA grants Fast Track designation for Farxiga in chronic kidney disease
|
27 August 2019 |
|
AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
|
23 August 2019 |
|
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
|
20 August 2019 |
|
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
|
14 August 2019 |